Anzeige
Mehr »
Donnerstag, 18.06.2026 - Börsentäglich über 12.000 News
Warum dieser 19M-CAD-Silber-Junior fast 1 Mio. Unzen Gold versteckt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMBD | ISIN: CA52731E1060 | Ticker-Symbol: 75J
Frankfurt
07.05.26 | 09:10
0,025 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEVELJUMP HEALTHCARE CORP Chart 1 Jahr
5-Tage-Chart
LEVELJUMP HEALTHCARE CORP 5-Tage-Chart

Aktueller Chart LEVELJUMP HEALTHCARE Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
LEVELJUMP HEALTHCARE CORP-Investoren interessieren sich auch für diese Wertpapiere
IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA ClearanceIncrease driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated...
► Artikel lesen
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq ComplianceProactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical...
► Artikel lesen
IceCure Medical: IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class OverbookedAt the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors =3 cm and...
► Artikel lesen
PROCEPT BioRobotics Reports First Quarter 2026 Financial ResultsSAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
PROCEPT BioRobotics: EAU Guidelines Upgrade Aquablation Therapy to Strong Surgical Recommendation for BPHUpdated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23...
► Artikel lesen
PROCEPT BioRobotics Announces International Launch of the HYDROS Robotic System, Expanding Global Access to AI-Enabled Aquablation TherapyUK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq:...
► Artikel lesen